International Journal on Magnetic Particle Imaging IJMPI
Vol. 9 No. 1 Suppl 1 (2023): Int J Mag Part Imag
https://doi.org/10.18416/IJMPI.2023.2303058

Proceedings Articles

Resotran® meets MPI – clinically approved Ferucarbotran reintroduced: a major leap towards MPI in humans

Main Article Content

Viktor Hartung (Department of Diagnostic and Interventional Radiology, University Hospital, Würzburg, Germany), Johanna Günther (Department of Expermental Physics 5 (Biophysics), Julius-Maximilians University, Würzburg, Germany), Anne Marie Augustin (Department of Diagnostic and Interventional Radiology, University Hospital, Würzburg, Germany), Teresa Reichl (Department of Expermental Physics 5 (Biophysics), Julius-Maximilians University, Würzburg, Germany), Philipp Gruschwitz (Department of Diagnostic and Interventional Radiology, University Hospital, Würzburg, Germany), Martin Rückert (Department of Expermental Physics 5 (Biophysics), Julius-Maximilians University, Würzburg, Germany), Thorsten Alexander Bley (Department of Diagnostic and Interventional Radiology, University Hospital, Würzburg, Germany), Volker Behr (Department of Expermental Physics 5 (Biophysics), Julius-Maximilians University, Würzburg, Germany), Stefan Herz , Patrick Vogel (Department of Expermental Physics 5 (Biophysics), Julius-Maximilians University, Würzburg, Germany)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

MPI has been on a trajectory towards clinical application in humans for years. As scanners and techniques mature, clinical testing is effectively prohibited by the lack of a clinically approved tracer. This changes now by the reintroduction of a Ferucarbotran-based tracer into the market, Resotran®. Although initially intended for use in MRI, we tested Resotran® for its viability in MPI. The other Ferucarbotran-based tracer fit for MRI and MPI is Resovist®, which is well known and characterized but was discontinued years ago. We present initial data on the characterization of Resotran® in comparison to Resovist®.

Article Details

References

[1] X. Han et al., The Applications of Magnetic Particle Imaging: from cell to body, diagnostics, vol. 10:0800, 2020
[2] S. Harvell-Smith et al., Magnetic Particle Imaging: tracer development and the biomedical applications of a radiation-free, sensitive, and quantitative imaging modality, Nanoscale, vol. 14:3658, 2020
[3] S. Biederer et al., Magnetization response spectroscopy of superparamagnetic nanoparticles for magnetic particle imaging, J Phys D, vol. 42(20), 2009
[4] P. Vogel et al., Critical Offset Magnetic Particle Spectroscopy for rapid and highly sensitive medical point-of-care diagnostics, Nat Comms, vol. 13:7230, 2022
[5] P. Vogel et al., iMPI – portable human-sized Magnetic Particle Imaging Scanner for real-time endovascular Interventions, PREPRINT (Version 1) available at Research Square doi:10.21203/rs.3.rs-2294644/v1, 2022.
[6] P. Vogel et al., Flexible and Dynamic Patch Reconstruction for Traveling Wave Magnetic Particle Imaging, Int J Magn Part Imag,, vol. 2(2):1611001, 2016
[7] P. Vogel et al., Low Latency Real-time Reconstruction for MPI Systems, Int J Magn Part Imag, vol. 3(2):1707002, 2017
[8] S. Dadfar et al, Size-isolation of superparamagnetic iron oxide nanoparticles improves MRI, MPI and hyperthermia performance, J Nanobiotechnol 18, 22 (2020)

Most read articles by the same author(s)

1 2 3 > >>